Abdominal radiology (New York) · 2026
Drug-eluting bead transarterial chemoembolization treatment of liver-dominant metastatic leiomyosarcoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Henning Jonathan, Venkat Shree, Kumar Premsai, El-Haddad Ghassan, Brohl Andrew, Ribeiro Mauricio, Mhaskar Rahul, Naghavi Arash, Druta Mihaela, Kis Bela
Аннотация
PURPOSE: To analyze the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment of unresectable metastatic hepatic leiomyosarcoma.
METHODS: Medical records and imaging of patients with metastatic leiomyosarcoma to the liver who underwent doxorubicin DEB-TACE from December 2014 to September 2024 were retrospectively reviewed to evaluate survival and clinical and biochemical toxicities.
RESULTS: The study included 29 patients (9 males, 20 females; average age 60.1 ± 12.7 years). Twenty-three patients (79.3%) had bilobar and 6 patients (20.7%) had unilobar disease. Twenty patients (69%) had extrahepatic metastases at the time of the first DEB-TACE. Twenty-five patients (86%) received systemic therapies before DEB-TACE, and 5 of these patients had hepatic metastasectomy. The median overall survival (OS) from the first DEB-TACE was 16.3 months (95% CI 2.2; 30.4), from diagnosis of liver metastasis was 35.8 months (95% CI 21.0; 50.6), and from primary diagnosis was 67.5 months (95% CI 49.2; 85.8). At 3 months post-DEB-TACE, the objective response was 79% (23 out of 29 patients), and the disease control rate was 96% (28 out of 29 patients), evaluated by mRECIST. The median liver progression-free survival from the first DEB-TACE was 7.8 months (95% CI 4.5; 11.2). There were two grade 3 clinical toxicities, four grade 3 laboratory toxicities, and 20 grade 1 or 2 laboratory toxicities. There was no 30-day mortality and no mortality related to DEB-TACE.
CONCLUSION: DEB-TACE is safe and effective treatment in patients with liver-dominant unresectable leiomyosarcoma with minimal side effects. The 35.8 months median OS from diagnosis of liver metastasis is very promising in this patient population with unresectable, chemotherapy-refractory disease.
METHODS: Medical records and imaging of patients with metastatic leiomyosarcoma to the liver who underwent doxorubicin DEB-TACE from December 2014 to September 2024 were retrospectively reviewed to evaluate survival and clinical and biochemical toxicities.
RESULTS: The study included 29 patients (9 males, 20 females; average age 60.1 ± 12.7 years). Twenty-three patients (79.3%) had bilobar and 6 patients (20.7%) had unilobar disease. Twenty patients (69%) had extrahepatic metastases at the time of the first DEB-TACE. Twenty-five patients (86%) received systemic therapies before DEB-TACE, and 5 of these patients had hepatic metastasectomy. The median overall survival (OS) from the first DEB-TACE was 16.3 months (95% CI 2.2; 30.4), from diagnosis of liver metastasis was 35.8 months (95% CI 21.0; 50.6), and from primary diagnosis was 67.5 months (95% CI 49.2; 85.8). At 3 months post-DEB-TACE, the objective response was 79% (23 out of 29 patients), and the disease control rate was 96% (28 out of 29 patients), evaluated by mRECIST. The median liver progression-free survival from the first DEB-TACE was 7.8 months (95% CI 4.5; 11.2). There were two grade 3 clinical toxicities, four grade 3 laboratory toxicities, and 20 grade 1 or 2 laboratory toxicities. There was no 30-day mortality and no mortality related to DEB-TACE.
CONCLUSION: DEB-TACE is safe and effective treatment in patients with liver-dominant unresectable leiomyosarcoma with minimal side effects. The 35.8 months median OS from diagnosis of liver metastasis is very promising in this patient population with unresectable, chemotherapy-refractory disease.